---
title: Real-world effectiveness and safety of bulevirtide monotherapy for up to 96
  weeks in patients with HDV-related cirrhosis
date: '2025-01-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39793613/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250111170808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: BLV 2 mg/day monotherapy up to 96 weeks was safe and effective
  in patients with HDV-related cirrhosis. Virological and clinical responses increased
  over time. Liver-related complications were ...'
disable_comments: true
---
CONCLUSION: BLV 2 mg/day monotherapy up to 96 weeks was safe and effective in patients with HDV-related cirrhosis. Virological and clinical responses increased over time. Liver-related complications were ...